Patient Interaction Intelligence and Predictive AI Revenue Activation

Today we’re speaking with Amol Nirgudkar, CEO of Patient Prism, a top rated business intelligence platform that improves patient call-to-appointment conversion rates by 30%. Having analyzed over 300 million patient interactions, Patient Prism has built its platform around a single conviction: understanding what happens during a patient interaction is only valuable if it activates what happens next. In this interview, Nirgudkar explores the evolution from passive reporting to predictive AI revenue activation, a shift that aligns Patient Prism’s operational precision with the data-driven rigor Valitana’s users require to turn patient access into predictable financial performance.

Valitana is a platform purpose-built for institutional investment professionals, including the hedge funds, asset managers, and PE sponsors increasingly active in multi-location healthcare. Valitana understands that financial performance follows operational execution. Valitana was also named “Best CLO Data and Technology Provider – Innovation” at the 2026U.S. CLO Awards, presented by DealCatalyst, and was previously ranked number one in three categories in the 2023 Creditflux CLO Census. Trusted by over 650 active users daily, Valitana brings the same data-driven rigor to investment decision-making that Patient Prism brings to patient revenue operations.

Q1. Analytics platforms spent the last decade solving for visibility: better dashboards, more granular reporting, deeper attribution. That era seems to be shifting. What shifted, and what's the thesis that replaces it?

The visibility era delivered something real: healthcare organizations finally understood what was happening across their patient interactions at scale. But visibility has a ceiling. A dashboard showing 30 percent of new patient calls go unconverted does not book those patients. Organizations reached the point where they had more data than they could act on, and revenue problems persisted anyway. The thesis that replaces it is predictive AI revenue activation. Understanding what happened during a patient interaction is only valuable if it activates change in what happens next. Patient Prism turns interaction data into specific, timely workflows that move missed opportunities toward booked appointments, across every touchpoint: phone calls, text inquiries, web forms, and online scheduling. For multi-location healthcare organizations, same-store revenue grow this often a patient interaction execution problem. The organizations recognizing that are the ones closing the gap between what their data says and what their P&L shows.

Q2. Unstructured conversational data is one of the hardest asset classes to extract signal from. With over 300 million patient interactions analyzed, what have you learned about the mechanics of turning messy human dialogue into something a platform can act on?

Healthcare conversations are uniquely layered. A single interaction can pivot from a routine scheduling request to a sensitive cost objection. These high-stakes moments serve as a litmus test for front-desk staff, where the difference between a patient felt heard and a patient lostdepends entirely on the quality of the engagement. Collapsing those into one outcome metric throws away most of what matters. Patient interaction intelligence requires a healthcare-specific model of what good looks like; that is not transferable from horizontal tools built for otherindustries. What makes signal actionable is connecting it to a specific next step: a near real-time follow-up for a patient who expressed interest but did not book, a coaching flag for a team member struggling with objections, a campaign adjustment based on which inquiries areconverting versus leaking.

Q3. Even when organizations have the right data in front of them, most teams don't change behavior. Why is the gap between insight and adoption so persistent, and what does it actually take to close it?

Dashboards do not change behavior. They inform behavior, and only when the person looking at them is motivated, has time to act, and knows what action to take. Those conditions rarely coexist in a busy multi-location healthcare operation.

The gap persists because most platforms surface findings after the fact. A weekly report on last week's missed opportunities is discouraging, not motivating. The follow-up window has closed. Closing the gap requires three things working together: near real-time routing of recovery opportunities; coaching tools that make insight specific and behavioral rather than statistical;and performance infrastructure that makes execution visible and accountable at every level of the organization. For investors evaluating multi-location healthcare platforms, this is worth understanding: the difference between a portfolio company that converts its patient interactiondata into revenue and one that does not is rarely a data problem. It is an execution infrastructure problem, and it is addressable. We have seen significant appointment conversion improvements in select deployments where organizations implement all three components together.

Q4. Private equity sponsors are increasingly treating operational data inside portfoliocompanies as a leading indicator of investment performance. What should sophisticated investors actually be looking at, and where do boards and deal teams still miss signal?

The most common gap is treating patient interaction data as an operational metric rather than afinancial one. Conversion rate on new patient inquiries is the operational metric that leads revenue per location. Sophisticated investors need to understand that relationship explicitly.

What deal teams often miss is the distinction between marketing performance and revenue execution performance. Strong inquiry volume with flat same-store growth usually means the execution layer is failing, and it rarely surfaces in standard diligence. The leading indicatorsworth tracking: new patient inquiry conversion rates by location, recovery rates on unconverted inquiries, and conversion variance across comparable locations in the same market. Meaningful differences there are almost never a demand problem. They are an execution problem, and theyare addressable. Patient Prism has tracked 12.4 million calls in the past year alone, groundingits benchmarks in real cross-organization data.

Q5. AI-powered capabilities are becoming central to patient interaction and revenueintelligence platforms. What applications deliver durable operational value, and how doyou distinguish those from capabilities that underperform in practice?

The applications delivering durable value are attached to execution outcomes: workflows thatroute recovered patient opportunities to the right team member in near real-time, tools thatsurface specific coaching insights from patient interactions, capabilities that identify whichlocations have execution gaps and what type. These hold up because they are measuredagainst booked appointments and recovered revenue, not engagement with a dashboard.

What tends to underperform is summarization layered on top of data that organizations werealready not acting on. A more sophisticated summary of an unaddressed problem is not asolution. The applications with the strongest track record treat the point of patient contact as thepoint of leverage, and they use predictive AI revenue activation to support the peopleresponsible for converting inquiries into scheduled care. For sophisticated investors, theevaluative question is straightforward: does a given capability move the conversion rate, or doesit move the slide deck? Those are not the same thing, and the difference shows up insame-store revenue growth.